@article{AMJ4405,
author = {Panagiotis J. Vlachostergios and Giuseppe Galletti and Scott T. Tagawa},
title = {Abiraterone survival benefit is independent of pain, prostate-specific antigen and Gleason sum in men with chemo-naïve metastatic castration-resistant prostate cancer (analysis of COU-AA-302)},
journal = {AME Medical Journal},
volume = {3},
number = {4},
year = {2018},
keywords = {},
abstract = {Advanced prostate cancer (PC), including metastatic castration-resistant prostate cancer (mCRPC) represents the lethal form of PC, yet remains largely dependent on androgen signaling (1). Abiraterone acetate (AA) is a steroid 17-hydroxylase/C17,20-lyase (CYP17) inhibitor targeting testicular, adrenal and intratumoral androgen production.},
issn = {2520-0518}, url = {https://amj.amegroups.org/article/view/4405}
}